ALIGOS THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
ALIGOS THERAPEUTICS INC. - More news...
ALIGOS THERAPEUTICS INC. - More news...
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
- Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
- Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
- Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
- Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
- Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
- Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
- Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
- Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
- Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
- Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
- Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)
- Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
- Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
- Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
- Aligos Therapeutics Announces $92 Million Private Placement Financing
- Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
- Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
- Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
- Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
- Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
- Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
- Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023